Advances in the medical therapy of inflammatory bowel disease

Current Opinion in Gastroenterology

Volumn 18, Issue 4, 2002, Pages 435-440

  Katz, Jeffry A ^a  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALICAFORSEN; AZATHIOPRINE; CYCLOSPORIN; ETANERCEPT; HEPARIN; IMMUNOMODULATING AGENT; INFLIXIMAB; MERCAPTOPURINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NATALIZUMAB; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROBIOTIC AGENT; ROSIGLITAZONE; TACROLIMUS; THALIDOMIDE; TIOGUANINE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

CROHN DISEASE; DISEASE MARKER; ENTERITIS; HUMAN; INTESTINE FLORA; REVIEW; SACCHAROMYCES CEREVISIAE; ULCERATIVE COLITIS;

EID: 0036088586     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001574-200207000-00007     Document Type: Review

References (50)

1. Use of serologic tests in Crohn's disease
2. Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic antibodies in inflammatory bowel disease
3. Comparative study of ASCA (anti-Saccharomyces cerevisiae antibody) assays in inflammatory bowel disease
4. Evaluation of serologic disease markers in a population-based cohort of patients with ulcerative colitis and Crohn's disease
5. Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease
6. Measurement of thiopurine methyltransferase activity and azathioprine metabolites in patients with inflammatory bowel disease
7. An open-label pilot study using thioguanine as a therapeutic alternative in Crohn's disease patients resistant to 6-mercaptopurine therapy
8. Is mycophenolate mofetil an effective alternative in azathioprine-intolerant patients with chronic active Crohn's disease?
9. Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis
10. Cyclosporin for severe ulcerative colitis does not increase the rate of perioperative complications
11. Tacrolimus: A new immunosuppressant for steroid refractory inflammatory bowel disease
12. Oral tacrolimus long-term therapy in patients with Crohn's disease and steroid resistance
13. Integrating anti-tumor necrosis factor therapy in inflammatory bowel disease: Current and future perspectives
14. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor a for Crohn's disease
15. Infliximab for the treatment of fistulas in patients with Crohn's disease
16. Clinical experience with infliximab therapy in 100 patients with Crohn's disease
17. Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: The first 100 patients
18. Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease
19. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease
20. Treatment of Crohn's disease (CD): Response to Remicade® (infliximab) in the ACCENT I trial through week 54
21. Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: A pilot study
22. Infliximab for refractory ulcerative colitis
23. Tuberculosis associated with infliximab, a tumor necrosis factor α-neutralizing agent
24. An engineered human antibody to TNF (CDP571) for active Crohn's disease: A randomized double-blind placebo-controlled trial
25. Etanercept in the treatment of active refractory Crohn's disease: A single-center pilot trial
26. Etanercept for active Crohn's disease: A randomized, double-blind, placebo-controlled trial
27. Attenuation of colitis in the cotton-top tamarin by anti-alpha4 integrin monoclonal antibody
28. A randomized placebo-controlled trial of a humanized monoclonal antibody to α4 integrin in active Crohn's disease
29. A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease
30. Absence of efficacy of subcutaneous antisense ICAM-1 treatment of chronic active Crohn's disease
31. Experimental models of inflammatory bowel disease
32. Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD)
33. Inflammatory bowel disease: Immunodiagnostics, immunotherapeutics, and ecotherapeutics
34. Germinated barley foodstuff. A novel neutraceutical therapeutic strategy for ulcerative colitis
35. Probiotics in human medicine
36. Lactobacillus species prevents colitis in interleukin 10 gene-deficient mice
37. Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis
38. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: A randomised trial
39. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: A double-blind, placebo-controlled trial
40. Is Lactobacillus GG helpful in children with Crohn's disease? Results of a preliminary, open-label study
41. Probiotic bacteria enhance murine and human intestinal epithelial barrier function
42. Expression of cytokines, inducible nitric oxide synthase, and matrix metalloproteinases in pouchitis: Effects of probiotic treatment
43. An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease
44. Thalidomide therapy for patients with refractory Crohn's disease: An open-label trial
45. Efficacy of long-term treatment with thalidomide in children and young adults with Crohn's disease: Preliminary results
46. A multicenter, randomized, controlled trial of heparin for the treatment of ulcerative colitis
47. Unfractionated heparin in the therapy of patients with highly active inflammatory bowel disease
48. Paradoxical response to heparin in 10 patients with ulcerative colitis
49. Low-dose low-molecular weight heparin (enoxaparin) is effective as adjuvant treatment in active ulcerative colitis. An open trial
50. An open-label trial of the PPARγ ligand rosiglitazone for active ulcerative colitis